Beyond Compliance. Strategic Clarity for Drug Compounding.
Compounding Strategy Advisors designs regulatory strategies grounded in decades of FDA policy leadership, translating complex requirements into sustainable, operational solutions that stand up to regulatory scrutiny.
Beyond Compliance
The Compounding Regulatory Landscape Is Complex — and Constantly Evolving.
Our Services
Strategic Advisory Across the Compounding Ecosystem
Regulatory Strategy & Risk Assessment
Learn More
Post-Inspection & Enforcement Response
Strategic response development for Warning Letters, Untitled Letters, and Form 483 observations. Regulatory meeting preparation, comprehensive gap analysis, and remediation strategies designed to de-escalate enforcement and restore Agency confidence.
Learn More
Policy & Compliance Program Development
Compliance program design grounded in regulatory intent, SOP framework evaluation, FD&C Act compliance guidance, adverse event reporting strategy, and labeling review. Programs built to withstand scrutiny — not just pass a checklist.
Learn More
Compounding Intelligence and Surveillance
Investment due diligence, executive briefings, advocacy strategy, and regulatory interpretation for law firms, investors, associations, and state boards. Strategic clarity for every organization that intersects with the compounding sector.
Learn More
Compounding Strategy Advisors, LLC
Former FDA Senior Leadership
National Policy Architects
Direct experience developing national compounding policy and implementing the Compounding Quality Act.
Inspection & Enforcement Leaders
Federal–State Expertise
Patient Safety Mission
An unwavering commitment to patients relying on compounded medications drugs every recommendation we make.
Decades of FDA Experience.
One Shared Mission.
Our guidance is rooted in the belief that responsible, high quality compounding, which prioritizes patient safety and regulatory alignment, ultimately drives business success
Frequently Asked Questions
A few questions that we’re often asked about our approach, experience, and how we work with clients.
Are you still affiliated with the FDA?
How is a "strategy-first" approach different from a standard audit?
Can you help us with an active Warning Letter or Form 483?
Do you work with both 503A pharmacies and 503B outsourcing facilities?
We're uncertain about engaging former FDA leadership. Why should we?